[{"id":"ea8aa5eb-747e-43c1-9888-86c7239699c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00547196","created_at":"2021-01-18T01:59:32.370Z","updated_at":"2024-07-02T16:34:25.798Z","phase":"","brief_title":"AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies \u0026 Disorders","source_id_and_acronym":"NCT00547196","lead_sponsor":"City of Hope Medical Center","biomarkers":" KMT2A • HLA-DRB1 • HLA-B","pipe":"","alterations":" ","tags":["KMT2A • HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • fludarabine IV • busulfan • cyclosporine • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 08/16/2005","start_date":" 08/16/2005","primary_txt":" Primary completion: 11/11/2009","primary_completion_date":" 11/11/2009","study_txt":" Completion: 05/28/2024","study_completion_date":" 05/28/2024","last_update_posted":"2024-06-14"},{"id":"1fc39e25-1922-47e5-b3b9-847ab787c19c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03842696","created_at":"2021-01-18T18:58:09.458Z","updated_at":"2025-02-25T16:25:22.587Z","phase":"Phase 1/2","brief_title":"Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation","source_id_and_acronym":"NCT03842696","lead_sponsor":"University of Michigan Rogel Cancer Center","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Zolinza (vorinostat) • cyclosporine"],"overall_status":"Recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 02/04/2020","start_date":" 02/04/2020","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-04-02"},{"id":"58325824-732c-4519-aaf2-9bb65afc637a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00544115","created_at":"2021-01-18T01:58:43.943Z","updated_at":"2024-07-02T16:35:11.891Z","phase":"Phase 2","brief_title":"Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders","source_id_and_acronym":"NCT00544115","lead_sponsor":"City of Hope Medical Center","biomarkers":" HLA-DRB1 • HLA-B","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • etoposide IV • sirolimus • melphalan • fludarabine IV • busulfan • cyclosporine • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 260","initiation":"Initiation: 10/16/2001","start_date":" 10/16/2001","primary_txt":" Primary completion: 03/13/2007","primary_completion_date":" 03/13/2007","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-04-02"},{"id":"43b99dac-6097-46d8-a900-4109c55cc2e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03434730","created_at":"2021-01-18T16:56:32.937Z","updated_at":"2024-07-02T16:35:16.606Z","phase":"Phase 2","brief_title":"Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation","source_id_and_acronym":"NCT03434730","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" KMT2A","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Actemra IV (tocilizumab) • cyclosporine • Neupogen (filgrastim)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 02/07/2018","start_date":" 02/07/2018","primary_txt":" Primary completion: 02/07/2025","primary_completion_date":" 02/07/2025","study_txt":" Completion: 02/07/2025","study_completion_date":" 02/07/2025","last_update_posted":"2024-03-04"},{"id":"67197a8d-9a9a-4c72-90a0-5288f05dfc03","acronym":"","url":"https://clinicaltrials.gov/study/NCT00357565","created_at":"2021-01-18T01:14:22.260Z","updated_at":"2024-07-02T16:35:22.043Z","phase":"Phase 2","brief_title":"Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia","source_id_and_acronym":"NCT00357565","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" KMT2A","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • fludarabine IV • busulfan • cyclosporine • Neupogen (filgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/01/2005","start_date":" 11/01/2005","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-01-26"},{"id":"6358176d-fc44-4d02-9e47-56116f950879","acronym":"","url":"https://clinicaltrials.gov/study/NCT00574496","created_at":"2021-01-18T02:05:52.845Z","updated_at":"2024-07-02T16:35:35.650Z","phase":"Phase 2","brief_title":"Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma","source_id_and_acronym":"NCT00574496","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD20 • HLA-DRB1 • HLA-B","pipe":"","alterations":" ","tags":["CD20 • HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • cyclophosphamide • ifosfamide • vincristine • vinorelbine tartrate • prednisone • melphalan • fludarabine IV • Matulane (procarbazine hydrochloride) • cyclosporine • Mustargen (mechlorethamine)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 11/13/2007","start_date":" 11/13/2007","primary_txt":" Primary completion: 08/02/2022","primary_completion_date":" 08/02/2022","study_txt":" Completion: 08/02/2022","study_completion_date":" 08/02/2022","last_update_posted":"2023-09-27"},{"id":"b77bf75c-b84b-4373-9687-867a97189f17","acronym":"","url":"https://clinicaltrials.gov/study/NCT00003838","created_at":"2021-01-17T22:53:23.367Z","updated_at":"2024-07-02T16:35:36.368Z","phase":"Phase 2","brief_title":"Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow","source_id_and_acronym":"NCT00003838","lead_sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","biomarkers":" MYC • BCL2 • CD34","pipe":" | ","alterations":" MYC translocation","tags":["MYC • BCL2 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclosporine"],"overall_status":"Completed","enrollment":" Enrollment 202","initiation":"Initiation: 04/15/1999","start_date":" 04/15/1999","primary_txt":" Primary completion: 12/14/2018","primary_completion_date":" 12/14/2018","study_txt":" Completion: 06/18/2020","study_completion_date":" 06/18/2020","last_update_posted":"2023-09-21"},{"id":"0d3ee8f5-d80e-4d1b-9490-6b52ff00aad7","acronym":"","url":"https://clinicaltrials.gov/study/NCT00816413","created_at":"2021-07-05T16:06:13.151Z","updated_at":"2024-07-02T16:35:40.198Z","phase":"Phase 1/2","brief_title":"Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer","source_id_and_acronym":"NCT00816413","lead_sponsor":"University of Nebraska","biomarkers":" HLA-B • HLA-C","pipe":" | ","alterations":" Chr del(5q) • Chr del(7q)","tags":["HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(5q) • Chr del(7q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclosporin A microemulsion • pentostatin • cyclosporine • ondansetron intravenous"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/01/2008","start_date":" 09/01/2008","primary_txt":" Primary completion: 02/01/2010","primary_completion_date":" 02/01/2010","study_txt":" Completion: 02/01/2010","study_completion_date":" 02/01/2010","last_update_posted":"2023-08-14"},{"id":"9b267266-fb73-416e-a6a5-a59554610bb0","acronym":"","url":"https://clinicaltrials.gov/study/NCT00014508","created_at":"2022-01-21T21:53:45.487Z","updated_at":"2024-07-02T16:35:45.176Z","phase":"Phase 2","brief_title":"Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma","source_id_and_acronym":"NCT00014508","lead_sponsor":"Eastern Cooperative Oncology Group","biomarkers":" HLA-B","pipe":"","alterations":" ","tags":["HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • fludarabine IV • cyclosporine • Leukine (sargramostim)"],"overall_status":"Completed","enrollment":"","initiation":"Initiation: 11/19/2001","start_date":" 11/19/2001","primary_txt":" Primary completion: 02/01/2007","primary_completion_date":" 02/01/2007","study_txt":" Completion: 05/27/2011","study_completion_date":" 05/27/2011","last_update_posted":"2023-06-22"},{"id":"caa1a5d9-83ef-4452-95d2-ca9cb8771e67","acronym":"","url":"https://clinicaltrials.gov/study/NCT00630253","created_at":"2021-01-18T02:20:37.574Z","updated_at":"2024-07-02T16:36:23.195Z","phase":"Phase 1/2","brief_title":"Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia","source_id_and_acronym":"NCT00630253","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" HLA-DRB1 • HLA-B","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclosporine • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 02/17/2000","start_date":" 02/17/2000","primary_txt":" Primary completion: 10/10/2020","primary_completion_date":" 10/10/2020","study_txt":" Completion: 10/10/2020","study_completion_date":" 10/10/2020","last_update_posted":"2021-10-12"},{"id":"5f58e372-e1e5-4755-993d-8ec12f5756c7","acronym":"","url":"https://clinicaltrials.gov/study/NCT00741455","created_at":"2021-01-18T02:48:01.529Z","updated_at":"2024-07-02T16:36:38.285Z","phase":"","brief_title":"Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies","source_id_and_acronym":"NCT00741455","lead_sponsor":"Dartmouth-Hitchcock Medical Center","biomarkers":" CD38","pipe":" | ","alterations":" CD38 expression","tags":["CD38"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclosporine • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 06/01/2004","start_date":" 06/01/2004","primary_txt":" Primary completion: 05/01/2020","primary_completion_date":" 05/01/2020","study_txt":" Completion: 05/01/2020","study_completion_date":" 05/01/2020","last_update_posted":"2020-11-23"},{"id":"6e2635e5-8b6b-4276-85a3-1ead01efd26e","acronym":"BIG-1","url":"https://clinicaltrials.gov/study/NCT02416388","created_at":"2021-01-18T11:32:41.418Z","updated_at":"2024-07-02T16:36:39.837Z","phase":"Phase 2/3","brief_title":"Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR","source_id_and_acronym":"NCT02416388 - BIG-1","lead_sponsor":"University Hospital, Angers","biomarkers":" FLT3 • NPM1","pipe":" | ","alterations":" FLT3-ITD mutation • NPM1 mutation","tags":["FLT3 • NPM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • NPM1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • daunorubicin • dexamethasone • idarubicin hydrochloride • cyclosporine • Qinprezo (vosaroxin)"],"overall_status":"Recruiting","enrollment":" Enrollment 3100","initiation":"Initiation: 01/01/2015","start_date":" 01/01/2015","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":"","study_completion_date":"","last_update_posted":"2020-10-20"},{"id":"ee9a82ff-9d07-40c0-aa40-35c972c3dfe2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00309842","created_at":"2021-01-18T01:03:54.232Z","updated_at":"2024-07-02T16:36:41.141Z","phase":"Phase 2","brief_title":"Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases","source_id_and_acronym":"NCT00309842","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" KMT2A • IKZF1","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["KMT2A • IKZF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclosporine • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 213","initiation":"Initiation: 07/28/2005","start_date":" 07/28/2005","primary_txt":" Primary completion: 07/29/2019","primary_completion_date":" 07/29/2019","study_txt":" Completion: 11/22/2019","study_completion_date":" 11/22/2019","last_update_posted":"2020-09-10"},{"id":"65ef933e-5bd4-4594-99fd-d1500caca8a8","acronym":"","url":"https://clinicaltrials.gov/study/NCT00068523","created_at":"2021-01-18T00:10:09.988Z","updated_at":"2024-07-02T16:36:42.765Z","phase":"","brief_title":"Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies","source_id_and_acronym":"NCT00068523","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" CCND1 • HLA-B","pipe":"","alterations":" ","tags":["CCND1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclosporine • cyclophosphamide intravenous • methylprednisolone oral • methylprednisolone sodium succinate"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 06/01/2003","start_date":" 06/01/2003","primary_txt":" Primary completion: 03/01/2004","primary_completion_date":" 03/01/2004","study_txt":"","study_completion_date":"","last_update_posted":"2020-07-27"},{"id":"d40d35ff-6123-4d22-bb83-b5ad34453c16","acronym":"","url":"https://clinicaltrials.gov/study/NCT00006451","created_at":"2021-01-17T23:53:49.514Z","updated_at":"2024-07-02T16:36:51.910Z","phase":"Phase 3","brief_title":"Bone Marrow Transplantation in Treating Patients With Leukemia","source_id_and_acronym":"NCT00006451","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • cyclosporine"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 04/01/1996","start_date":" 04/01/1996","primary_txt":" Primary completion: 11/01/2000","primary_completion_date":" 11/01/2000","study_txt":" Completion: 11/01/2000","study_completion_date":" 11/01/2000","last_update_posted":"2020-01-03"},{"id":"a17ffe57-fe51-4cfc-be1c-843d4dbb12e1","acronym":"","url":"https://clinicaltrials.gov/study/NCT00185692","created_at":"2021-01-18T00:37:49.022Z","updated_at":"2024-07-02T16:36:52.917Z","phase":"Phase 2","brief_title":"Allogeneic Transplantation From Related Haploidentical Donors","source_id_and_acronym":"NCT00185692","lead_sponsor":"Stanford University","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclosporine • methylprednisolone acetate • methylprednisolone sodium succinate"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 08/01/2000","start_date":" 08/01/2000","primary_txt":" Primary completion: 12/01/2010","primary_completion_date":" 12/01/2010","study_txt":" Completion: 12/01/2010","study_completion_date":" 12/01/2010","last_update_posted":"2019-12-04"},{"id":"33e1da73-3fd8-41e5-b11d-9c4167b56563","acronym":"","url":"https://clinicaltrials.gov/study/NCT00085449","created_at":"2022-01-21T21:54:04.321Z","updated_at":"2024-07-02T16:36:53.140Z","phase":"Phase 1/2","brief_title":"Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer","source_id_and_acronym":"NCT00085449","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Campath (alemtuzumab) • melphalan • fludarabine IV • cyclosporine"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/01/2006","start_date":" 05/01/2006","primary_txt":" Primary completion: 01/01/2007","primary_completion_date":" 01/01/2007","study_txt":" Completion: 01/01/2007","study_completion_date":" 01/01/2007","last_update_posted":"2019-11-27"},{"id":"eb20b8a5-3ed9-42db-92ae-f5d814060799","acronym":"Interfant06","url":"https://clinicaltrials.gov/study/NCT00550992","created_at":"2021-01-18T02:00:23.012Z","updated_at":"2024-07-02T16:36:57.586Z","phase":"","brief_title":"Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia","source_id_and_acronym":"NCT00550992 - Interfant06","lead_sponsor":"Dutch Childhood Oncology Group","biomarkers":" KMT2A • CD34","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement • CD34 positive","tags":["KMT2A • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement • CD34 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • cyclophosphamide • etoposide IV • vincristine • prednisone • daunorubicin • mitoxantrone • leucovorin calcium • melphalan • Oncaspar liquid (pegaspargase) • mercaptopurine • busulfan • thioguanine • cyclosporine • prednisolone"],"overall_status":"Unknown status","enrollment":" Enrollment 445","initiation":"Initiation: 01/01/2006","start_date":" 01/01/2006","primary_txt":" Primary completion: 12/01/2020","primary_completion_date":" 12/01/2020","study_txt":"","study_completion_date":"","last_update_posted":"2019-07-30"},{"id":"d52b4991-f938-4515-90d6-a54cf018b5a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT00987480","created_at":"2021-01-18T03:51:26.016Z","updated_at":"2024-07-02T16:37:09.086Z","phase":"Phase 2","brief_title":"Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine","source_id_and_acronym":"NCT00987480","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • busulfan • cyclosporine"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 09/25/2009","start_date":" 09/25/2009","primary_txt":" Primary completion: 07/10/2017","primary_completion_date":" 07/10/2017","study_txt":" Completion: 07/10/2017","study_completion_date":" 07/10/2017","last_update_posted":"2018-07-10"},{"id":"74721f7c-7902-41c0-817b-c62cf0b48d54","acronym":"","url":"https://clinicaltrials.gov/study/NCT00365287","created_at":"2021-01-18T01:16:06.199Z","updated_at":"2024-07-02T16:37:16.010Z","phase":"Phase 1/2","brief_title":"Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer","source_id_and_acronym":"NCT00365287","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" KMT2A • HLA-DRB1 • HLA-B","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["KMT2A • HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclosporine"],"overall_status":"Completed","enrollment":" Enrollment 148","initiation":"Initiation: 06/01/2000","start_date":" 06/01/2000","primary_txt":" Primary completion: 12/01/2005","primary_completion_date":" 12/01/2005","study_txt":" Completion: 12/01/2005","study_completion_date":" 12/01/2005","last_update_posted":"2017-11-29"},{"id":"ff47f4e1-258d-4a31-8283-04bc54b8ba68","acronym":"","url":"https://clinicaltrials.gov/study/NCT00290641","created_at":"2021-01-18T00:59:28.290Z","updated_at":"2024-07-02T16:37:16.014Z","phase":"","brief_title":"Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer","source_id_and_acronym":"NCT00290641","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" HLA-DRB1 • HLA-B","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclosporine • Neupogen (filgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 04/01/2001","start_date":" 04/01/2001","primary_txt":" Primary completion: 01/01/2006","primary_completion_date":" 01/01/2006","study_txt":" Completion: 01/01/2006","study_completion_date":" 01/01/2006","last_update_posted":"2017-11-29"},{"id":"8cd8fe7b-ebe0-43c8-9f1c-f9dbc47220ed","acronym":"","url":"https://clinicaltrials.gov/study/NCT00425802","created_at":"2021-01-18T01:30:03.359Z","updated_at":"2024-07-02T16:37:16.750Z","phase":"Phase 2","brief_title":"Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT00425802","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD20 • HLA-DRB1 • CD4","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • HLA-DRB1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • fludarabine IV • cyclosporine • Neupogen (filgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 61","initiation":"Initiation: 11/28/2006","start_date":" 11/28/2006","primary_txt":" Primary completion: 10/28/2016","primary_completion_date":" 10/28/2016","study_txt":" Completion: 10/28/2016","study_completion_date":" 10/28/2016","last_update_posted":"2017-10-31"},{"id":"1403ecda-4eb2-4815-a282-7d8e1f830b9f","acronym":"","url":"https://clinicaltrials.gov/study/NCT00301834","created_at":"2021-01-18T01:01:58.975Z","updated_at":"2024-07-02T16:37:17.471Z","phase":"Phase 2","brief_title":"Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders","source_id_and_acronym":"NCT00301834","lead_sponsor":"University of California, San Francisco","biomarkers":" CD34 • HLA-B","pipe":"","alterations":" ","tags":["CD34 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Campath (alemtuzumab) • fludarabine IV • busulfan • cyclosporine"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 01/01/2005","start_date":" 01/01/2005","primary_txt":" Primary completion: 09/01/2011","primary_completion_date":" 09/01/2011","study_txt":" Completion: 09/01/2011","study_completion_date":" 09/01/2011","last_update_posted":"2017-09-28"},{"id":"55515aa9-7775-40bc-96cb-9d24aff090e5","acronym":"","url":"https://clinicaltrials.gov/study/NCT00043979","created_at":"2021-01-29T06:54:03.771Z","updated_at":"2024-07-02T16:37:21.539Z","phase":"Phase 2","brief_title":"Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas","source_id_and_acronym":"NCT00043979","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • sirolimus • melphalan • fludarabine IV • cyclosporine • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 09/19/2002","start_date":" 09/19/2002","primary_txt":" Primary completion: 05/01/2009","primary_completion_date":" 05/01/2009","study_txt":" Completion: 12/14/2011","study_completion_date":" 12/14/2011","last_update_posted":"2017-05-31"}]